Literature DB >> 28985084

Controlling Plasma Stability of Hydroxamic Acids: A MedChem Toolbox.

Paul Hermant1, Damien Bosc1, Catherine Piveteau1, Ronan Gealageas1, BaoVy Lam1, Cyril Ronco1, Matthieu Roignant1, Hasina Tolojanahary1, Ludovic Jean2, Pierre-Yves Renard2, Mohamed Lemdani3, Marilyne Bourotte1, Adrien Herledan1, Corentin Bedart1, Alexandre Biela1, Florence Leroux1, Benoit Deprez1, Rebecca Deprez-Poulain1,4.   

Abstract

Hydroxamic acids are outstanding zinc chelating groups that can be used to design potent and selective metalloenzyme inhibitors in various therapeutic areas. Some hydroxamic acids display a high plasma clearance resulting in poor in vivo activity, though they may be very potent compounds in vitro. We designed a 57-member library of hydroxamic acids to explore the structure-plasma stability relationships in these series and to identify which enzyme(s) and which pharmacophores are critical for plasma stability. Arylesterases and carboxylesterases were identified as the main metabolic enzymes for hydroxamic acids. Finally, we suggest structural features to be introduced or removed to improve stability. This work thus provides the first medicinal chemistry toolbox (experimental procedures and structural guidance) to assess and control the plasma stability of hydroxamic acids and realize their full potential as in vivo pharmacological probes and therapeutic agents. This study is particularly relevant to preclinical development as it allows obtaining compounds equally stable in human and rodent models.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28985084     DOI: 10.1021/acs.jmedchem.7b01444

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.

Authors:  Samuel Bouchet; Camille Linot; Dusan Ruzic; Danica Agbaba; Benoit Fouchaq; Joëlle Roche; Katarina Nikolic; Christophe Blanquart; Philippe Bertrand
Journal:  ACS Med Chem Lett       Date:  2019-05-09       Impact factor: 4.345

2.  Identification of 3-hydroxy-1,2-dimethylpyridine-4(1H)-thione as a metal-binding motif for the inhibition of botulinum neurotoxin A.

Authors:  Lucy Lin; Lewis D Turner; Peter Šilhár; Sabine Pellett; Eric A Johnson; Kim D Janda
Journal:  RSC Med Chem       Date:  2020-11-12

Review 3.  A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019).

Authors:  Sida Shen; Alan P Kozikowski
Journal:  Expert Opin Ther Pat       Date:  2019-12-25       Impact factor: 6.674

4.  OleD Loki as a Catalyst for Hydroxamate Glycosylation.

Authors:  Ryan R Hughes; Khaled A Shaaban; Larissa V Ponomareva; Jamie Horn; Chunhui Zhang; Chang-Guo Zhan; S Randal Voss; Markos Leggas; Jon S Thorson
Journal:  Chembiochem       Date:  2019-11-26       Impact factor: 3.164

5.  Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington's Disease.

Authors:  Andrew J Stott; Michel C Maillard; Vahri Beaumont; David Allcock; Omar Aziz; Alexander H Borchers; Wesley Blackaby; Perla Breccia; Gillian Creighton-Gutteridge; Alan F Haughan; Rebecca E Jarvis; Christopher A Luckhurst; Kim L Matthews; George McAllister; Scott Pollack; Elizabeth Saville-Stones; Amanda J Van de Poël; Huw D Vater; Julie Vann; Rachel Williams; Dawn Yates; Ignacio Muñoz-Sanjuán; Celia Dominguez
Journal:  ACS Med Chem Lett       Date:  2021-02-11       Impact factor: 4.345

6.  Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype.

Authors:  Olasunkanmi O Olaoye; Paris R Watson; Nabanita Nawar; Mulu Geletu; Abootaleb Sedighi; Shazreh Bukhari; Yasir S Raouf; Pimyupa Manaswiyoungkul; Fettah Erdogan; Ayah Abdeldayem; Aaron D Cabral; Muhammad Murtaza Hassan; Krimo Toutah; Andrew E Shouksmith; Justyna M Gawel; Johan Israelian; Tudor B Radu; Niyati Kachhiyapatel; Elvin D de Araujo; David W Christianson; Patrick T Gunning
Journal:  J Med Chem       Date:  2021-02-12       Impact factor: 7.446

Review 7.  The Rebirth of Matrix Metalloproteinase Inhibitors: Moving Beyond the Dogma.

Authors:  Gregg B Fields
Journal:  Cells       Date:  2019-08-27       Impact factor: 6.600

8.  Peptides Derived from Vascular Endothelial Growth Factor B Show Potent Binding to Neuropilin-1.

Authors:  Filipa Mota; Tamas Yelland; Jennie A Hutton; Jennifer Parker; Anastasia Patsiarika; A W Edith Chan; Andrew O'Leary; Constantina Fotinou; John F Martin; Ian C Zachary; Snezana Djordjevic; Paul Frankel; David L Selwood
Journal:  Chembiochem       Date:  2021-11-03       Impact factor: 3.164

Review 9.  Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development.

Authors:  Yurong Lai; Xiaoyan Chu; Li Di; Wei Gao; Yingying Guo; Xingrong Liu; Chuang Lu; Jialin Mao; Hong Shen; Huaping Tang; Cindy Q Xia; Lei Zhang; Xinxin Ding
Journal:  Acta Pharm Sin B       Date:  2022-03-17       Impact factor: 14.903

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.